Items where authors include "Owen, R.G."

Number of items: 18.

Article

Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026

Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026

Tam, C.S. orcid.org/0000-0002-9759-5017, Opat, S., D'Sa, S. et al. (33 more authors) (2024) Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia. Blood Advances, 8 (7). pp. 1639-1650. ISSN 2473-9529

Giles, H.V., Drayson, M.T., Kishore, B. et al. (11 more authors) (2024) Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry. Blood Cancer Journal, 14. 50. ISSN 2044-5385

de Tute, R.M., Cook, G. orcid.org/0000-0003-1717-0412, Cairns, D.A. orcid.org/0000-0002-2338-0179 et al. (12 more authors) (2024) Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial. Bone Marrow Transplantation, 59 (3). pp. 431-434. ISSN 0268-3369

de Tute, R.M., Cook, G. orcid.org/0000-0001-7196-7364, Cairns, D.A. orcid.org/0000-0002-2338-0179 et al. (12 more authors) (2024) Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial. Bone Marrow Transplantation, 59. pp. 431-434. ISSN 0268-3369

Jones, J.R., Cairns, D.A. orcid.org/0000-0002-2338-0179, Menzies, T. et al. (14 more authors) (2023) Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. eClinicalMedicine, 62. 102099. ISSN 2589-5370

Jenner, M.W., Pawlyn, C., Davies, F.E. et al. (15 more authors) (2023) The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology, 201 (2). pp. 267-279. ISSN 0007-1048

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Barrans, S.L., Fenton, J.A.L., Banham, A. et al. (2 more authors) (2004) Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood, 104 (9). pp. 2933-2935. ISSN 0006-4971

Barrans, S.L., Evans, P.A.S., O’Connor, S.J.M. et al. (5 more authors) (2003) The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clinical Cancer Research, 9 (6). pp. 2133-2139. ISSN 1078-0432

Barrans, S.L., Carter, I., Owen, R.G. et al. (5 more authors) (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 99 (4). pp. 1136-1143. ISSN 0006-4971

Proceedings Paper

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07-10 Dec 2024, San Diego, USA. American Society of Hematology , pp. 385-386.

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. In: Blood. The 66th ASH Annual Meeting, 07 Dec 2024, San Diego, USA. American Society of Hematology , pp. 673-674.

Pawlyn, C., Menzies, T. orcid.org/0000-0003-3896-7228, Davies, F.E. et al. (12 more authors) (2020) The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial. In: Blood. 62nd ASH Annual Meeting and Exposition, 05-08 Dec 2020, Virtual. American Society of Hematology , pp. 40-43.

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Pawlyn, C., Davies, F.E., Kaiser, M.F. et al. (18 more authors) (2016) Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

This list was generated on Wed Apr 2 19:11:54 2025 BST.